Validation of a predictive model that identifies patients at high risk of developing febrile neutropaenia following chemotherapy for breast cancer.
about
Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study.Clinical predictive models for chemotherapy-induced febrile neutropenia in breast cancer patients: a validation study.Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review.Full-dose chemotherapy in early stage breast cancer regardless of absolute neutrophil count and without G-CSF does not increase chemotherapy-induced febrile neutropenia.Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors.Sepsis biomarkers in neutropaenic systemic inflammatory response syndrome patients on standard care wards.High-throughput pharmacogenetics identifies SLCO1A2 polymorphisms as candidates to elucidate the risk of febrile neutropenia in the breast cancer RAPP-01 trial.Drug-related genetic polymorphisms affecting severe chemotherapy-induced neutropenia in breast cancer patients: A hospital-based observational study.External validation of a risk model of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma.Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer.
P2860
Q30975418-14D52607-B42A-40A4-B5B2-75578B09E05FQ33778817-5B82680E-B3BE-4ECA-A94B-1C85ADE0428EQ35303471-7D4E4841-9B22-4513-A1FE-EE4449CD3F0EQ38109529-63B5B4BB-49C2-4DAC-8C28-387CBCC5CB70Q38613025-CCF68935-D816-4009-92C6-A2DE44BE31E3Q39386095-A5D4D13D-A871-4F49-A40D-DA61C3431CA2Q41441391-7F724D4D-9108-49E7-A407-7C8C4C6E50FAQ41484971-88137020-3298-432D-B103-B9E17577C0A4Q44569718-B856F2D7-6E6A-4F7F-9115-67F6EDC5ABA0Q51712236-662682AE-0C65-47CC-99EC-AF0BCC416763
P2860
Validation of a predictive model that identifies patients at high risk of developing febrile neutropaenia following chemotherapy for breast cancer.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Validation of a predictive mod ...... hemotherapy for breast cancer.
@en
type
label
Validation of a predictive mod ...... hemotherapy for breast cancer.
@en
prefLabel
Validation of a predictive mod ...... hemotherapy for breast cancer.
@en
P2093
P2860
P356
P1433
P1476
Validation of a predictive mod ...... hemotherapy for breast cancer.
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDR493
P577
2011-11-02T00:00:00Z